Chutes & Ladders—Metabolic disorder biotech lands industry vet as CMO

  Chutes and LaddersWelcome to this week’s Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Gabrielle Masson and it will be featured here at the end of each week.

Metabolic disorder biotech taps former Pfizer vet to serve as CMO

MBX Biosciences

Longtime biopharma leader Salomon (Sam) Azoulay, M.D., has joined endocrine and metabolic disorder-focused MBX Biosciences, where he’ll serve as chief medical officer. 

Sam Azoulay, M.D.,

Sam Azoulay, M.D.(LinkedIn)

Azoulay most recently served as CMO at Roivant spinout Sumitovant Biopharma. Before that, he had held the same title at the parent company for almost two years.

Prior to Roivant, the physician-scientist spent 19 years serving in various leadership roles at Pfizer, including CMO of Pfizer Essential Health.

At MBx, Azoulay will guide global clinical…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks